Promising drug targets Hard-to-Treat meningioma in new trial

NCT ID NCT05425004

First seen Feb 20, 2026 · Last updated May 14, 2026 · Updated 10 times

Summary

This study tests the drug cabozantinib in 24 people with meningioma (a type of brain tumor) that has returned or worsened after standard treatments like surgery or radiation. The main goal is to see if the drug can stop the tumor from growing for at least 6 months. Participants must have a performance status of 50 or higher and adequate blood counts.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 100653, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Miami Cancer Institute at Baptist Health, Inc.

    RECRUITING

    Miami, Florida, 33176, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Vanderbilt University Medical Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.